


Amendment to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the present patent application.

Listing of Claims:

1. (Currently Amended) A compound of the formula




wherein

X is absent or trans or cis CHCH[[,]];

R₁ is (C₁-C₁₀) alkyl unsubstituted or substituted by one to three hydroxy, ~~(C₁-C₁₀) alkenyl~~ (C₂-C₁₀) alkenyl unsubstituted or substituted by one to three hydroxy, ~~(C₁-C₁₀) alkynyl~~ (C₂-C₁₀) alkynyl unsubstituted or substituted by one to three hydroxy, or aryl unsubstituted or substituted by one to three hydroxy;

R₂ is hydrogen, alkyl or aryl; and

R₃ and R₄ are, independently of each other, H, halogen, or ~~a solubilizing group~~



wherein:

P and R are each independently selected from CH₂, CH₂CH₂ and CH₂CHT where T is alkyl, and Q is O, S, NH or NCH₃.

with the proviso that at least one of R₃ and R₄ is halogen, and that when R₄ is halogen and R₃ is hydrogen, neither R₁ nor R₂ are alkyl;

or a pharmaceutically acceptable salt thereof.

2. **(Previously presented)** The compound according to claim 1, wherein R₁ is aryl unsubstituted or substituted by one to three hydroxy and R₂ is hydrogen.

3. **(Canceled).**

4. **(Previously presented)** The compound according to claim 1, wherein R₄ is a halogen.

5-6. **(Canceled).**

7. **(Currently amended)** The compound according to claim ~~[[6]]~~ 1, wherein R₃ is a halogen and R₄ is a hydrogen or partial formula (1.2) wherein Q is O, S, NH or NCH₃.

8. **(Canceled).**

9. **(Currently Amended)** The compound according to claim 1, wherein R₃ or R₄ is an amine-containing heterocycle, wherein the amine is a ring member of the heterocycle.

10. **(Currently Amended)** The compound according to claim 1, wherein R₃ or R₄ is N-methylpiperazine, wherein the N-methylpiperazine is attached through its unsubstituted ring nitrogen.

11. **(Previously presented)** The compound according to claim 1 wherein X is trans CHCH.

12. **(Currently Amended)** The compound according to claim 1, wherein R₁ is ~~hydroxyethanol, hydroxyaniline, hydroxyphenyl, 2-hydroxyethanol, 4-hydroxyaniline, or 4-hydroxyphenyl,~~ wherein the point of attachment of 2-hydroxyethanol is at the 1 position and the point of attachment of 4-hydroxyphenyl is at the 1 position.

13-17. **(Canceled).**

18. **(Currently Amended)** The compound according to claim 1, wherein R₂ is phenyl, substituted phenyl, ~~pyranyl~~-substituted pyridinyl, thiophenyl, substituted thiophenyl, furanyl, substituted furanyl, thiazole, oxazole or substituted or unsubstituted imidazole.

19. **(Currently Amended)** The compound according to claim 12, wherein R₂ is N-alkyl imidazole, wherein the point of attachment is at the 2, 4 or 5 position.

20. **(Currently Amended)** The compound according to claim 1 of the formula 6-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-(p-hydroxyanilino)-quinazoline, wherein vinyl is cis or trans.

21. **(Currently Amended)** The compound according to claim 1 of the formula 7-(4-methylpiperazino)-6-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-(p-hydroxyanilino)-quinazoline, wherein vinyl is cis or trans.

22. **(Currently Amended)** ~~The compound according to claim 1 of the formula~~ The process according to claim 39, wherein the compound of formula (1.6) is 6-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-chloroquinazoline, wherein vinyl is cis or trans.

23. **(Currently Amended)** ~~The compound according to claim 1 of the formula~~ The process according to claim 39, wherein the compound of formula (1.6) is 7-(4-methylpiperazino)-6-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-chloroquinazoline, wherein vinyl is cis or trans.

24. **(Currently Amended)** ~~The compound according to claim 1 of the formula~~ The process according to claim 39, wherein the compound of formula (1.5) is 6-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-(3H)quinazolinone, wherein vinyl is cis or trans.

25. **(Currently Amended)** ~~The compound according to claim 1 of the formula~~ The process according to claim 39, wherein the compound of formula (1.5) is 7-(4-methylpiperazino)-6-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-(3H) quinazolinone, wherein vinyl is cis or trans.

26-28. **(Canceled).**

29. **(Previously presented)** A method for preventing or treating a bacterial infection in a human or an animal, comprising administering to said human or said animal a prophylactically or therapeutically effective amount of a compound according to claim 1, effective in preventing or treating the bacterial infection.


30. **(Canceled).**

31. **(Previously presented)** A method for antiseptis of, or disinfecting or sterilizing the surface of an object, including a human, of bacteria, comprising: contacting the object with the compound according to claim 1 in an amount and for a time sufficient to achieve a desired degree of antiseptis, disinfection or sterilization.


32-38. **(Canceled).**

39. **(Currently amended)** A process for the preparation of the compound according to claim 1 comprising:


a) optionally reacting a compound of formula (1. 3)




with hydrochloric acid, acetic anhydride and aqueous ammonia, to form a compound of formula (1.4)



b) ~~optionally~~ reacting the compound of formula 1.4 with 5-nitro-2-furancarboxaldehyde, to form a compound of formula (1.5)



c) ~~optionally~~ reacting the compound of formula 1.5 with phosphorus pentachloride and phosphorus oxychloride to form a compound of formula (1.6)



and

d) reacting the compound of formula 1.6 with a compound of the formula (1.7)



wherein X is H and R₁, R₂, R₃, and R₄ are as defined in claim 1, with the proviso that at least one of R₃ and R₄ is halogen, and that when R₄ is halogen and R₃ is hydrogen, neither R₁ nor R₂ are alkyl.

40-42. (Canceled).

43. (New) The compound according to claim 19, wherein the point of attachment is at the 2 position.

44. **(New)** The compound according to claim 1 of the formula 7-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-(p-hydroxyanilino)-quinazoline, wherein vinyl is cis or trans.

45. **(New)** The compound according to claim 1 of the formula 6-(morpholino)-7-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-(p-hydroxyanilino)-quinazoline, wherein vinyl is cis or trans.

46. **(New)** The process according to claim 39, wherein the compound of formula (1.6) is 7-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-chloroquinazoline, wherein vinyl is cis or trans.

47. **(New)** The process according to claim 39, wherein the compound of formula (1.6) is 6-(morpholino)-7-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-chloroquinazoline, wherein vinyl is cis or trans.

48. **(New)** The process according to claim 39, wherein the compound of formula (1.5) is 7-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-(3H)quinazolinone, wherein vinyl is cis or trans.

49. **(New)** The process according to claim 39, wherein the compound of formula (1.5) is 6-(morpholino)-7-fluoro-2-[2-(5-nitro-2-furyl) vinyl]-4-(3H) quinazolinone, wherein vinyl is cis or trans.